↓ Skip to main content

Cochrane Database of Systematic Reviews

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

Overview of attention for article published in this source, August 2011
Altmetric Badge

Mentioned by

twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
51 Mendeley
connotea
1 Connotea
Title
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma
Published by
John Wiley & Sons, Ltd, August 2011
DOI 10.1002/14651858.cd007941.pub2
Pubmed ID
Authors

Bauer, Kathrin, Skoetz, Nicole, Monsef, Ina, Engert, Andreas, Brillant, Corinne

Abstract

There are two different international standards for the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL): chemotherapy with escalated BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone) regimen and chemotherapy with ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) regimen.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 2%
Unknown 50 98%

Demographic breakdown

Readers by professional status Count As %
Other 7 14%
Researcher 6 12%
Student > Ph. D. Student 6 12%
Student > Master 5 10%
Student > Bachelor 4 8%
Other 11 22%
Unknown 12 24%
Readers by discipline Count As %
Medicine and Dentistry 22 43%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Biochemistry, Genetics and Molecular Biology 3 6%
Agricultural and Biological Sciences 2 4%
Philosophy 1 2%
Other 4 8%
Unknown 15 29%